Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B

Kai-Ti Lin, Yu-Ming Yeh, Chi-Mu Chuang, Scarlett Y. Yang, Jer-Wei Chang, Shu-Pin Sun, Yi-Shiang Wang, Kuan-Chong Chao () and Lu-Hai Wang ()
Additional contact information
Kai-Ti Lin: Institute of Molecular and Genomic Medicine, National Health Research Institutes
Yu-Ming Yeh: Institute of Molecular and Genomic Medicine, National Health Research Institutes
Chi-Mu Chuang: Taipei Veterans General Hospital
Scarlett Y. Yang: Institute of Molecular and Genomic Medicine, National Health Research Institutes
Jer-Wei Chang: Institute of Molecular and Genomic Medicine, National Health Research Institutes
Shu-Pin Sun: Institute of Molecular and Genomic Medicine, National Health Research Institutes
Yi-Shiang Wang: Institute of Molecular and Genomic Medicine, National Health Research Institutes
Kuan-Chong Chao: Taipei Veterans General Hospital
Lu-Hai Wang: Institute of Molecular and Genomic Medicine, National Health Research Institutes

Nature Communications, 2015, vol. 6, issue 1, 1-13

Abstract: Abstract Glucocorticoids are widely used in conjunction with chemotherapy for ovarian cancer to prevent hypersensitivity reactions. Here we reveal a novel role for glucocorticoids in the inhibition of ovarian cancer metastasis. Glucocorticoid treatments induce the expression of miR-708, leading to the suppression of Rap1B, which result in the reduction of integrin-mediated focal adhesion formation, inhibition of ovarian cancer cell migration/invasion and impaired abdominal metastasis in an orthotopic xenograft mouse model. Restoring Rap1B expression reverts glucocorticoid-miR-708 cascade-mediated suppression of ovarian cancer cell invasion and metastasis. Clinically, low miR-708 and high Rap1B are found in late-state ovarian tumours, as compared with normal, and patients with high miR-708 show significantly better survival. Overall, our findings reveal an opportunity for glucocorticoids and their downstream mediators, miR-708 or Rap1B, as therapeutic modalities against metastatic ovarian epithelial cancer.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms6917 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms6917

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms6917

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().